SYH2053/placebo injection

DRUG2 trials

Sponsors

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Conditions

Hypercholesterolemia and Mixed HyperlipidemiaNon-familial Hypercholesterolemia and Mixed Hyperlipidemia

Phase 2

A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia

CompletedNCT07421232

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Hypercholesterolemia and Mixed Hyperlipidemia

Start: 2024-12-03End: 2026-02-12Updated: 2026-02-19

Phase 3

A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia on a Background of Lipid-lowering Therapy

Not yet recruitingNCT07421284

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Non-familial Hypercholesterolemia and Mixed Hyperlipidemia

Start: 2026-03-31End: 2028-01-31Target: 900Updated: 2026-02-19